Holen Sie sich die Stockscreener-App
77.20
4.03%
2.99
Handel nachbörslich:
77.95
0.75
+0.97%
Schlusskurs vom Vortag:
$74.21
Offen:
$73.97
24-Stunden-Volumen:
524.33K
Relative Volume:
1.23
Marktkapitalisierung:
$1.73B
Einnahmen:
$883.37M
Nettoeinkommen (Verlust:
$71.37M
KGV:
23.03
EPS:
3.3516
Netto-Cashflow:
$150.90M
1W Leistung:
+4.73%
1M Leistung:
+4.27%
6M Leistung:
-16.14%
1J Leistung:
+14.34%
1-Tages-Spanne:
$73.38
$78.33
1-Wochen-Bereich:
$73.38
$78.33
52-Wochen-Spanne:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
77.20 | 1.66B | 883.37M | 71.37M | 150.90M | 3.3516 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals Inc (ANIP) Trading 3.7% Higher on Apr 6 - gurufocus.com
Travel Stocks: Will ANI Pharmaceuticals Inc stock go up in YEAR2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn
ANI Pharmaceuticals: Worthy Of A Position - Seeking Alpha
A Look At ANI Pharmaceuticals (ANIP) Valuation After Mixed Short Term Share Price Moves - Sahm
Why ANI Pharmaceuticals (ANIP) Stands Out as a Leading Long-Term Growth Stock - Bitget
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term - Yahoo Finance
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance UK
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
Volume Recap: Can ANI Pharmaceuticals Inc beat the S P 5002026 Spike Watch & Consistent Return Investment Signals - baoquankhu1.vn
SG Americas Securities LLC Buys 73,334 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
Price Action: Why is ANI Pharmaceuticals Inc stock going upWeekly Market Report & Daily Entry Point Trade Alerts - baoquankhu1.vn
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - TradingView
Assenagon Asset Management S.A. Has $7.09 Million Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025 - AOL.com
ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025 - The Motley Fool
Is Record 2025 Sales And 2026 Guidance Past US$1 Billion Altering The Investment Case For ANI Pharmaceuticals (ANIP)? - Sahm
Vanguard (ANIP) amendment: reports 0 shares after Jan 12, 2026 realignment - Stock Titan
How The ANI Pharmaceuticals (ANIP) Investment Narrative Is Shifting With Updated Analyst Assumptions - Yahoo Finance
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims - TradingView
Risk Analysis: Will ANI Pharmaceuticals Inc announce a stock splitTrade Performance Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
Oliver Luxxe Assets LLC Invests $1.82 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Completion of Merger - Yahoo
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside Potential - Yahoo Finance
Assessing ANI Pharmaceuticals (ANIP) Valuation After Rare Disease Momentum And Alimera Acquisition - Sahm
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - TradingView
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Guggenheim Remains a Buy on ANI Pharmaceuticals (ANIP) - The Globe and Mail
ANIP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story - simplywall.st
EPS Watch: Can ANI Pharmaceuticals Inc lead its sector in growthQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - tradingview.com
ANIP PE Ratio & Valuation, Is ANIP Overvalued - Intellectia AI
IBRX Stock Jumps on Progress in NK Cell Therapy Production - TradingView
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak - AlphaStreet
234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP - MarketBeat
Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani pharmaceuticals SVP Rowland sells $357k in stock By Investing.com - au.investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Ani Pharmaceuticals SVP Cook sells $36k in stock - Investing.com
Ani Pharmaceuticals SVP Cook sells $36k in stock By Investing.com - Investing.com South Africa
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ani Pharmaceuticals Inc-Aktie (ANIP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mutz Christopher | HEAD OF RARE DISEASE |
Mar 13 '26 |
Sale |
71.64 |
3,162 |
226,526 |
91,309 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Mar 13 '26 |
Sale |
72.62 |
500 |
36,310 |
79,390 |
| Mutz Christopher | HEAD OF RARE DISEASE |
Mar 09 '26 |
Sale |
74.18 |
3,602 |
267,196 |
94,471 |
| Mutz Christopher | HEAD OF RARE DISEASE |
Mar 06 '26 |
Sale |
74.22 |
2,121 |
157,421 |
101,387 |
| Davis Krista | SVP, CHIEF HR OFFICER |
Mar 09 '26 |
Sale |
74.13 |
5,087 |
377,099 |
51,946 |
| Davis Krista | SVP, CHIEF HR OFFICER |
Mar 06 '26 |
Sale |
75.00 |
1,485 |
111,375 |
57,033 |
| CAREY STEPHEN P. | SVP & CFO |
Mar 05 '26 |
Option Exercise |
49.51 |
3,312 |
163,977 |
192,855 |
| CAREY STEPHEN P. | SVP & CFO |
Mar 05 '26 |
Sale |
75.50 |
7,312 |
552,031 |
185,543 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):